Abstract 352: Oral Cilostazol and High‐Dose Intravenous Albumin in Aneurysmal Subarachnoid Hemorrhage Patients with Refractory Cerebral Ischemia

Background and Purpose Cerebral ischemia associated with vasospasm in patients with aneurysmal subarachnoid hemorrhage (aSAH) requires a multifaceted approach. We report the use of the combination of enteral cilostazol and intravenous (IV) high‐dose albumin in aSAH patients with cerebral ischemia refractory to other accepted pharmacologic and endovascular treatments. Materials and Methods Three aSAH patients who developed cerebral ischemic symptoms despite treatment with oral nimodipine and endovascular measures (i.e., intraarterial vasodilators and balloon angioplasty) were treated with enteral cilostazol (200 mg/day) and one or more doses of IV (25%) albumin (1.25 g per kg over 8 hours). The patients were monitored by serial neurological examinations, transcranial Doppler imaging (TCDI) ultrasound, and computed tomographic angiography (CTA) and perfusion (CTP) scans. Results Three patients (ages 58, 67 and 56 years) developed symptomatic cerebral ischemia and vasospasm following an aSAH. Due to limited angiographic response to endovascular treatment, including intraarterial vasodilators with or without balloon angioplasty, IV (25%) albumin and enteral cilostazol were administered. CT angiogram and perfusion 2‐3 days post‐treatment demonstrated resolution of the perfusion deficits and angiographic vasospasm. Concurrently, TCDI demonstrated improved vasospasm and resolution of neurological deficits. None of the patients required any additional treatments for cerebral ischemia. Conclusions A combination of oral cilostazol and IV high dose (25%) albumin was associated with amelioration of angiographic vasospasm, reduction of tissue perfusion deficits, and clinical improvement of aSAH patients with severe refractory cerebral ischemia.